IMMunoglobulin G2
IMMunoglobulin G2 Basic information
- Product Name:
- IMMunoglobulin G2
- Synonyms:
-
- IMMunoglobulin G2
- Gevokizumab
- Research Grade Gevokizumab(DHB95602)
- Gevokizumab (anti-IL-1b)
- Research Grade Gevokizumab
- CAS:
- 1129435-60-4
- MW:
- 0
- Mol File:
- Mol File
IMMunoglobulin G2 Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
IMMunoglobulin G2 Usage And Synthesis
Uses
Gevokizumab is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II)[1][2].
in vivo
Gevokizumab (1 mg/kg; i.v.; once daily for 3 d) improves endothelial regrowth and reduces neointima formation in rats following carotid denudation[2].
| Animal Model: | Rat carotid denudation model in Sprague-Dawley rats (3-month0-old, 330-360 g)[2] |
| Dosage: | 1, 10 and 50 mg/kg |
| Administration: | Intravenous injection; once daily for 3 days |
| Result: | Decreased carotid intima-media thickness (IMT) in the proximal part of the denuded artery at day 28, and improved endothelial regrowth at 1 mg/kg.? |
References
[1] Issafras H, et al. Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1β antibody with differential receptor-modulating properties. J Pharmacol Exp Ther. 2014 Jan;348(1):202-15. DOI:10.1124/jpet.113.205443
[2] Roubille F, et al. The interleukin-1β modulator gevokizumab reduces neointimal proliferation and improves reendothelialization in a rat carotid denudation model. Atherosclerosis. 2014 Oct;236(2):277-85. DOI:10.1016/j.atherosclerosis.2014.07.012
IMMunoglobulin G2Supplier
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 0086-21-67651709
- cfx759@hotmail.com
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 15817493340
- 981810490@qq.com